RT Journal Article
SR Electronic
T1 Development of a SARS-CoV-2 total antibody assay and the dynamics of antibody response over time in hospitalized and non-hospitalized patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.17.20133793
DO 10.1101/2020.06.17.20133793
A1 Vogelzang, Erik H.
A1 Loeff, Floris C.
A1 Derksen, Ninotska IL
A1 Kruithof, Simone
A1 Heer, Pleuni Ooijevaar-de
A1 van Mierlo, Gerard
A1 Linty, Federica
A1 Mok, Juk Yee
A1 van Esch, Wim
A1 de Bruin, Sanne
A1 Vlaar, Alexander P.J.
A1 ,
A1 Seppen, Bart
A1 Leeuw, Maureen
A1 van Oudheusden, Anne J.G.
A1 Buiting, Anton G.M.
A1 Jim, Kin Ki
A1 Vrielink, Hans
A1 Swaneveld, Francis
A1 Vidarsson, Gestur
A1 van der Schoot, C. Ellen
A1 Wever, Peter
A1 Li, Wentao
A1 van Kuppeveld, Frank
A1 Murk, Jean-Luc
A1 Bosch, Berend Jan
A1 Wolbink, Gerrit-Jan
A1 Rispens, Theo
YR 2020
UL http://medrxiv.org/content/early/2020/06/19/2020.06.17.20133793.abstract
AB SARS-CoV-2 infections often cause only mild disease that may evoke relatively low antibody titers compared to patients admitted to hospitals. Generally, total antibody bridging assays combine good sensitivity with high selectivity. Therefore, we developed sensitive total antibody bridging assays for detection of SARS-CoV-2 antibodies to the receptor-binding domain (RBD) and nucleocapsid protein (NP), in addition to conventional isotype-specific assays. Antibody kinetics was assessed in PCR-confirmed hospitalized COVID-19 patients (n=41) and three populations of patients with COVID-19 symptoms not requiring hospital admission: PCR-confirmed convalescent plasmapheresis donors (n=182), PCR-confirmed hospital care workers (n=47), and a group of longitudinally sampled symptomatic individuals highly suspect of COVID-19 (n=14). In non-hospitalized patients, the antibody response to RBD is weaker but follows similar kinetics as has been observed in hospitalized patients. Across populations, the RBD bridging assay identified most patients correctly as seropositive. In 11/14 of the COVID-19-suspect cases, seroconversion in the RBD bridging assay could be demonstrated before day 12; NP antibodies emerged less consistently. Furthermore, we demonstrated the feasibility of finger prick sampling for antibody detection against SARS-CoV-2 using these assays. In conclusion, the developed bridging assays reliably detect SARS-CoV-2 antibodies in hospitalized and non-hospitalized patients, and are therefore well-suited to conduct seroprevalence studies.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been conducted in accordance with the ethical principles set out in the declaration of Helsinki and all participants provided written informed consent, if applicable. Approval was obtained from the Medical Ethics Committees from the Academic Medical Center, VU University Medical Center and Elisabeth-TweeSteden Hospital.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from this study are available upon reasonable request